select trial semaglutide ppt AHA Late Breaking Science: Day 1 Highlights π«SELECT Trial: Semaglutide and FLOWing with the SemagluTIDE β
Description
Patients with a history of motion sickness, cyclic vomiting, or gastroparesis tend to report more intense and longer-lasting nausea on GLP-1 receptor agonists [10]
Consuming much more than ~40 grams at once doesnt provide added benefit and could be less efficiently utilized
Bioavailability of the subcutaneous formulation is approximately 89%, ensuring consistent drug exposure across patients
Liquids pass through the stomach more rapidly than solids
doi: 10.1001/jamanetworkopen.2024.27258, 57
